Meta-Analysis
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 14, 2014; 20(22): 7034-7039
Published online Jun 14, 2014. doi: 10.3748/wjg.v20.i22.7034
Table 3 Characteristics of randomized comparisons of hyoscine butylbromide and placebo groups reported in the literature
StudyGroupPolyp detection rateAdenoma detection ratePolyps per patient (n)Adenomas per patient (n)
Byun et al[20]Hyoscine butylbromide45.6%35.0%NRNR
Placebo39.2%29.4%
Lee et al[21]Hyoscine butylbromide34.5%NR0.9 ± 1.8NR
Placebo25.9%0.6 ± 1.2
Corte et al[10]Hyoscine butylbromide43.6%27.1%0.91 ± 0.0840.55 ± 0.073
Placebo36.6%21.8%0.70 ± 0.0750.42 ± 0.062
de Brouwer et al[15]Hyoscine butylbromide55.9%29.7%1.13NR
Placebo60.2%31.4%1.21
Rondonotti et al[16]Hyoscine butylbromide38.6%31.7%NRNR
Placebo37.0%28%